Song Yujie, Jorgensen Christian
IRMB, CARTIGEN, University of Montpellier, Inserm, CHU de Montpellier, 34090 Montpellier, France.
Biomedicines. 2022 May 30;10(6):1278. doi: 10.3390/biomedicines10061278.
Osteoarthritis (OA) presents a major clinical challenge to rheumatologists and orthopedists due to the lack of available drugs reducing structural degradation. Mesenchymal stromal cells (MSCs) may represent new therapeutic approaches in cartilage regeneration. In this review, we highlight the latest knowledge on the biological properties of MSC, such as their chondrogenic and immunomodulatory potential, and we give a brief overview of the effects of MSCs in preclinical and clinical studies of OA treatment and also compare different MSC sources, with the adipose tissue-derived MSCs being promising. Then, we focus on their structural benefit in treating OA and summarize the current evidence for the assessment of cartilage in OA according to magnetic resonance imaging (MRI) and second-look arthroscopy after MSC therapy. Finally, this review provides a brief perspective on enhancing the activity of MSCs.
由于缺乏有效的减少结构退变的药物，骨关节炎（OA）给风湿病学家和骨科医生带来了重大的临床挑战。间充质基质细胞（MSCs）可能代表了软骨再生的新治疗方法。在这篇综述中，我们重点介绍了MSCs生物学特性的最新知识，例如它们的软骨生成和免疫调节潜能，简要概述了MSCs在OA治疗的临床前和临床研究中的作用，并比较了不同的MSCs来源，其中脂肪组织来源的MSCs很有前景。然后，我们关注它们在治疗OA方面的结构益处，并总结了目前根据磁共振成像（MRI）和MSCs治疗后二次关节镜检查评估OA中软骨的证据。最后，本综述简要展望了增强MSCs活性的方法。
